HNPP resulting from PMP22 gene deletion is a clinical disorder with mild symptoms and generally does not affect the carrier’s quality of life [28], as in the case of the proband in our study; however, the proband decided to abort the male fetus considering the potential risk of dystrophinopathies. This evidence concerns the gene PMP22 and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.